In response to questions we have received from you about challenges faced in trial participation during COVID-19, Sanofi Genzyme has provided the following information:

1) **Is home dosing available for participants in Sanofi Genzyme’s ASMD Clinical trials?**
   Sanofi Genzyme recognizes that this COVID-19 pandemic is a uniquely challenging time. We are committed to ensuring that patients have continuity, while prioritizing patient safety, and are working with investigators, country level teams, and individual patients, on a case by case basis to provide them the best option during COVID-19.

2) **How are you handling monitoring visits for patients who are unable to safely travel to their usual clinic site in NYC?**
   Where home visits are an option, and approved by the investigator, it is an option for study participants to have quarterly visits performed at home. The goal remains to have tests performed in a timely, safe fashion.

3) **I had extra blood drawn during my last trial monitoring visit. Why?**
   One outcome measure in this study is to check how Olipudase Alfa is processed by your body. From time to time additional samples may be drawn to help with those assessments. If you have additional questions, please consult your treating physician.

MAT-US-2010168 06/2020